HomeCompareBBMPY vs ABBV

BBMPY vs ABBV: Dividend Comparison 2026

BBMPY yields 9.10% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBMPY wins by $234676.55M in total portfolio value
10 years
BBMPY
BBMPY
● Live price
9.10%
Share price
$1.52
Annual div
$0.14
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$234676.65M
Annual income
$229,824,952,588.51
Full BBMPY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BBMPY vs ABBV

📍 BBMPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBMPYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBMPY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBMPY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBMPY
Annual income on $10K today (after 15% tax)
$773.50/yr
After 10yr DRIP, annual income (after tax)
$195,351,209,700.23/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BBMPY beats the other by $195,351,188,644.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBMPY + ABBV for your $10,000?

BBMPY: 50%ABBV: 50%
100% ABBV50/50100% BBMPY
Portfolio after 10yr
$117338.38M
Annual income
$114,912,488,680.14/yr
Blended yield
97.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BBMPY
No analyst data
Altman Z
0.6
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBMPY buys
0
ABBV buys
0
No recent congressional trades found for BBMPY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBMPYABBV
Forward yield9.10%3.06%
Annual dividend / share$0.14$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$234676.65M$102.3K
Annual income after 10y$229,824,952,588.51$24,771.77
Total dividends collected$234347.15M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BBMPY vs ABBV ($10,000, DRIP)

YearBBMPY PortfolioBBMPY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,520$1,820.00$11,550$430.00+$970.00BBMPY
2$17,656$4,259.14$13,472$627.96+$4.2KBBMPY
3$30,118$11,226.51$15,906$926.08+$14.2KBBMPY
4$68,022$35,796.07$19,071$1,382.55+$49.0KBBMPY
5$223,899$151,114.91$23,302$2,095.81+$200.6KBBMPY
6$1,169,296$929,724.16$29,150$3,237.93+$1.14MBBMPY
7$10,326,699$9,075,552.76$37,536$5,121.41+$10.29MBBMPY
8$160,864,963$149,815,394.96$50,079$8,338.38+$160.81MBBMPY
9$4,534,295,602$4,362,170,090.90$69,753$14,065.80+$4534.23MBBMPY
10$234,676,648,882$229,824,952,588.51$102,337$24,771.77+$234676.55MBBMPY

BBMPY vs ABBV: Complete Analysis 2026

BBMPYStock

BBMG Corporation, an investment holding company, engages in manufacturing and sale of cement and building materials in Asia, Europe, Africa, and internationally. The company's Cement and Ready-Mixed Concrete segment manufactures and sells cement and concrete. Its Modern Building Materials and Commerce and Logistics segment produces furniture and woods, decorative and fitting materials, and wall body and insulation materials; and offers commerce and logistics services. The company's Property Development segment develops and sells housing properties. Its Property Investment and Management segment invests in properties; and provides management and security services to residential and commercial properties. The company offers mortars and crushed stones, slag fine powders, coatings and construction hardware, glass made spectacle lenses, glass wool products, wood based panels, resins, building materials, limestone and cement clinkers, refractory materials and ceramics, aerated concrete products, machinery equipment and accessories, wind power equipment, doors and windows, and sanitary ceramics; wholesales coal, building and metal materials, and metal and metallic minerals; and imports and exports bulk commodities. It provides project and furniture decoration, construction contracting and project management, accommodation and conference, hotel management, finance leasing, property consultancy, property rental, technology development, goods transportation and storage, waste disposal, finance and financing advisory, exhibition, tourism, and knitting processing services; offers loading, offloading, and handling services; provides building material testing services; and operates sports projects, as well as publishes concrete world magazine, and provides advertising design and production services. The company was founded in 2005 and is headquartered in Beijing, the People's Republic of China.

Full BBMPY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BBMPY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBMPY vs SCHDBBMPY vs JEPIBBMPY vs OBBMPY vs KOBBMPY vs MAINBBMPY vs JNJBBMPY vs MRKBBMPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.